Denali Therapeutics Inc.
DNLI
$24.20
-$0.72-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.60M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.60M | -- | -- | -- | -- |
| Cost of Revenue | 400.81M | 406.40M | 418.78M | 420.66M | 416.95M |
| Gross Profit | -397.21M | -406.40M | -418.78M | -420.66M | -416.95M |
| SG&A Expenses | 144.74M | 140.72M | 136.56M | 127.16M | 116.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 545.55M | 547.12M | 555.34M | 547.82M | 533.58M |
| Operating Income | -541.95M | -547.12M | -555.34M | -547.82M | -533.58M |
| Income Before Tax | -511.35M | -507.92M | -512.44M | -498.68M | -478.97M |
| Income Tax Expenses | 102.00K | 102.00K | 102.00K | 68.00K | 68.00K |
| Earnings from Continuing Operations | -511.45 | -508.02 | -512.54 | -498.74 | -479.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -511.45M | -508.02M | -512.54M | -498.74M | -479.03M |
| EBIT | -541.95M | -547.12M | -555.34M | -547.82M | -533.58M |
| EBITDA | -526.06M | -531.76M | -540.53M | -534.17M | -521.52M |
| EPS Basic | -2.84 | -2.88 | -2.97 | -2.91 | -2.81 |
| Normalized Basic EPS | -1.78 | -1.81 | -1.88 | -1.86 | -1.79 |
| EPS Diluted | -2.84 | -2.88 | -2.97 | -2.91 | -2.81 |
| Normalized Diluted EPS | -1.78 | -1.81 | -1.88 | -1.86 | -1.79 |
| Average Basic Shares Outstanding | 721.83M | 705.97M | 690.55M | 685.18M | 682.21M |
| Average Diluted Shares Outstanding | 721.83M | 705.97M | 690.55M | 685.18M | 682.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |